Reference health
Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity
74/74 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
8 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 74 checked references that resolve
resolves10.15585/mmwr.mm655051e1
Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015
resolves10.15585/mmwr.mm6712a1
Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016
resolves10.1038/s41380-020-0661-4
The changing opioid crisis: development, challenges and opportunities
resolves10.1016/j.neuropharm.2017.10.016
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
resolves10.1093/jat/bks078
Analysis of Clothing and Urine from Moscow Theatre Siege Casualties Reveals Carfentanil and Remifentanil Use
resolves10.1016/j.jval.2017.07.014
Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom
resolves10.1016/S0140-6736(73)91879-5
TREATMENT OF DRUG OVERDOSAGE WITH NALOXONE, A SPECIFIC NARCOTIC ANTAGONIST
resolves10.1177/2042098617744161
Naloxone dosage for opioid reversal: current evidence and clinical implications
resolves10.1111/j.1360-0443.2005.01154.x
A multi‐center randomized trial of buprenorphine–naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
resolves10.1097/ADM.0000000000000486
Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence
resolves10.1016/j.drugalcdep.2018.07.019
Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months
resolves10.1016/j.drugalcdep.2019.107804
Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats
resolves10.1124/jpet.119.258566
Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis
resolves10.1016/j.neuropharm.2019.06.001
Development of vaccines to treat opioid use disorders and reduce incidence of overdose
resolves10.1016/j.pbb.2009.01.015
Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence
resolves10.1080/14760584.2017.1378577
Current status and future prospects for the development of substance abuse vaccines
resolves10.1016/j.vaccine.2006.01.047
A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents
resolves10.1021/acs.molpharmaceut.8b01296
Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation
resolves10.1016/j.jim.2014.01.010
Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse
resolves10.1080/21645515.2016.1212785
Biologics to treat substance use disorders: Current status and new directions
resolves10.1021/jm3013745
Reduced Antinociception of Opioids in Rats and Mice by Vaccination with Immunogens Containing Oxycodone and Hydrocodone Haptens
resolves10.1371/journal.pone.0096547
Effect of Currently Approved Carriers and Adjuvants on the Pre-Clinical Efficacy of a Conjugate Vaccine against Oxycodone in Mice and Rats
resolves10.1371/journal.pone.0101807
Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats
resolves10.1124/jpet.111.189506
An Oxycodone Conjugate Vaccine Elicits Drug-Specific Antibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate Analgesia
resolves10.1038/s41541-017-0013-9
Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
resolves10.1021/acs.jmedchem.7b01427
A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse
resolves10.1002/anie.201511654
Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs
resolves10.1021/acs.molpharmaceut.0c00497
Novel Vaccine That Blunts Fentanyl Effects and Sequesters Ultrapotent Fentanyl Analogues
resolves10.1124/jpet.118.253674
A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats
resolves10.1371/journal.pone.0184876
Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
resolves10.1124/jpet.120.000014
Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity
resolves10.1021/acs.molpharmaceut.8b00592
Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins
resolves10.1021/acsomega.8b01478
Improved Admixture Vaccine of Fentanyl and Heroin Hapten Immunoconjugates: Antinociceptive Evaluation of Fentanyl-Contaminated Heroin
resolves10.1016/j.pain.2004.03.024
Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain
resolves10.1371/journal.pone.0115696
Pharmacokinetic Correlates of the Effects of a Heroin Vaccine on Heroin Self-Administration in Rats
resolves10.1016/j.neuropharm.2018.06.026
Prophylactic vaccination protects against the development of oxycodone self-administration
resolves10.1038/s41386-019-0385-9
Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats
resolves10.3109/08923973.2016.1165246
The effect of preexisting anti-carrier immunity on subsequent responses to CRM<sub>197</sub>or Qb-VLP conjugate vaccines
resolves10.1016/j.clim.2005.07.005
Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation
resolves10.1021/ci300067q
On the Value of Homology Models for Virtual Screening: Discovering hCXCR3 Antagonists by Pharmacophore-Based and Structure-Based Approaches
resolves10.1016/j.drugalcdep.2019.06.006
Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone
resolves10.1021/acschemneuro.0c00064
Evaluation of a Dual Fentanyl/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats
resolves10.1016/j.vaccine.2012.08.064
Probing the protective effects of a conformationally constrained nicotine vaccine
resolves10.1021/ja034805t
A New Strategy for Improved Nicotine Vaccines Using Conformationally Constrained Haptens
resolves10.1074/jbc.273.44.28576
Crystal Structure of Monoclonal 6B5 Fab Complexed with Phencyclidine
resolves10.1016/j.jmb.2011.10.042
Different Binding Modes of Free and Carrier-Protein-Coupled Nicotine in a Human Monoclonal Antibody
resolves10.4049/jimmunol.1500385
The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse
resolves10.1016/j.drugalcdep.2015.06.014
Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats
resolves10.1021/mp900213u
A Critical Evaluation of a Nicotine Vaccine within a Self-Administration Behavioral Model
resolves10.1016/j.vaccine.2012.04.101
Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats
resolves10.1016/S1382-6689(97)00147-6
Dopamine D1 antagonist SCH23390 attenuates self-administration of both cocaine and fentanyl in rats
resolves10.1016/0014-2999(89)90358-0
Reinforcing effects of the enkephalin analogs, EK-209 and EK-399, in rats
resolves10.1016/j.pbb.2015.02.022
The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence
resolves10.1021/acschemneuro.6b00297
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects
resolves10.1021/jm051256o
Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand Complexes
The 8 references without a DOI — listed, not checked
no DOI — not checkedUnited Nations Office on
Drugs and Crime (UNODC). World Drug Report 2019; 2019.
no DOI — not checkedDrug Overdose Deaths in the United States, 1999–2018
no DOI — not checkedref11/cit11
no DOI — not checkedref17/cit17
no DOI — not checkedref21/cit21
no DOI — not checkedref74/cit74
no DOI — not checkedMethods in Molecular Biology
no DOI — not checkedCase, D. A.; Ben-Shalom, I. Y.; Brozell, S. R.; Cerutti, D. S.; T.E. Cheatham, I.; Cruzeiro, V. W. D.; Darden, T. A.; Duke, R. E.; Ghoreishi, D.; Gilson, M. K.; Goetz, H. G. W.; Greene, D.; Harris, R.; Homeyer, N.; Izadi, S.; Kovalenko, A.; Kurtzman, T.; Lee, T. S.; LeGrand, S.; Li, P.; Lin, C.; Liu, J.; Luchko, T.; Luo, R.; Mermelstein, D. J.; Merz, K. M.; Miao, Y.; Monard, G.; Nguyen, C.; Nguyen, H.; Omelyan, I.; Onufriev, A.; Pan, F.; Qi, R.; Roe, D. R.; Roitberg, A.; Sagui, C.; Schott-Verdugo, S.; Shen, J.; Simmerling, C. L.; Smith, J.; Salomon-Ferrer, R.; Swails, J.; Walker, R. C.; Wang, J.; Wei, H.; Wolf, R. M.; Wu, X.; Xiao, L.; York, D. M.; Kollman, P. A. AMBER 2018; 2018.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1021/acs.jmedchem.0c01042"><img src="https://citestamp.com/citestamped/10.1021/acs.jmedchem.0c01042/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1021/acs.jmedchem.0c01042)